Thalia Therapeutics Plc · LSE:THAT
Thalia Therapeutics — Investor Presentation (October 2023)
18 slides from Thalia Therapeutics's investor presentation, Oct 2, 2023
Slide 1: Nanogenics Acquisition September 2023
Nanogenics Acquisition September 2023 1
Slide 2: Disclaimer
Disclaimer This presentation, which comprises the presentation slides (the “Slides”) and any information communicated during any delivery of the presentation whether orally or in writing, including talks given by the presenters, any question and answer session and any documents or materials distribu
Slide 3: Introduction to N4 Pharma plc
Introduction to N4 Pharma plc • Pre-clinical stage specialist pharmaceutical company offering Nuvec®, a unique patented silica nanoparticle delivery system, for the reformulation and development of cancer treatments and vaccines using RNA • Strong market and investor focus on the delivery of RNA the
Slide 4: Nuvec® System
Nuvec® System The Nuvec® delivery system has unique characteristics compared to existing delivery systems: • Unique spiky structure to allow binding of siRNA • Simple process to load multiple siRNAs onto same nanoparticle • Protects siRNA from enzymatic digestion and pH exposure • Thermostability –
Slide 5: Nuvec mode of action
Nuvec mode of action Click here to see a video of how Nuvec® works 5
Slide 6: Current Nuvec® R&D programme: Dual siRNA in cancer resistance
Current Nuvec® R&D programme: Dual siRNA in cancer resistance Nuvec® has ability to By dual or mulitple Potentially leading to a • Combination therapy is the Deliver both siRNAs siRNA loading on one reduction in relapse main means of preventing to same cell particle during cancer resistance (e.g. an
Slide 7: Current R&D: dual loading pre-clinical model
Current R&D: dual loading pre-clinical model • Test dual loading of Nuvec®, with siRNA in a clinically relevant PC9 cancer cell model • Two siRNA compounds to be simultaneously loaded targeting both the epithelial growth factor receptor (EGF-R), to prevent cell growth and B-Cell Lymphoma 2 (BCL-2) t
Slide 8: Opportunity
opportunity • Proprietary delivery technology • LipTide®: Patented peptide and lipid based delivery system for nucleic acids. • Peptide binds payload and targets specific cells • Lipid allows for efficient endosomal release into the cell • siRNA Therapeutics • Proprietary siRNA sequence for reducing
Slide 9: The LipTide® delivery platform is a peptide/lipid nanoparticle
The LipTide® delivery platform is a peptide/lipid nanoparticle Lipid (10-20%) Payload Spacer Uptake targeting binding/core Peptide core [K]16 -G-A- + Payload (80-90%) The peptide mediates cell uptake as absence of targeting sequence dramatically reduces cell uptake LipTide acts like an ‘artificial v
Slide 10: Glaucoma Commercial Opportunity
Glaucoma Commercial Opportunity 2 • Total Glaucoma Treatment Market size exceeded USD 5.5 billion in 2021 and is expected to witness over 3.2% CAGR from 2022 to 2028 • In 2020, more than 75 million people worldwide were affected by glaucoma • Growing prevalence of glaucoma worldwide • Growth driven
Slide 11: Glaucoma Problem and The Solution
Glaucoma Problem • Surgery (trabeculectomy) is widely used to lower intraocular pressure when pharmaceutical management is unsuccessful. This creates a channel into a reservoir (bleb) underneath the surface of the eye • The natural response of the body is to ‘heal’ this newly made drain. This fibros
Slide 12: ECP105
ECP105 • ECP105 is designed to enhance glaucoma outcomes post- surgery without toxic side effects • In vitro proof of concept demonstrated siRNA inhibition of proteins related to fibrosis and ophthalmic indications • Positive preliminary data for delivery (siRNA) and efficacy in vivo for prevention
Slide 13: ECP105 Preliminary data
ECP105 Preliminary data5-7 Following a single subconjunctival administration of LipTide® containing a MRTF-B siRNA (ECP105 prototype, MRTF-B LYR); • MRTF mRNA expression reduced by 30% • Immunohistochemistry revealed less scarring versus untreated • Bleb survival increased from 11 days to 22 days •
Slide 14: Nanogenics Scientific Team
Nanogenics Scientific Team • Professor Alex Mullen at the University of Strathclyde [UoS] (Formulation PI) • 30 years+ of academic experience in parenteral and colloidal drug delivery system development • Pharma consultant with extensive experience of being an expert court witness in patent litigati
Slide 15: Use of placing funds
Use of placing funds £300k £50k for initial investment into Nanogenics deal costs (£250k investment £50k loan*) Results of successfully completed pre-clinical project (12-15 months) expected to deliver the following: • Identified optimal lead formulation / siRNA sequence • Demonstrated in vivo effic
Slide 16: ECP105 Next Steps
ECP 105 Next Steps • Move ECP105 into First-in-Human studies • In vivo GLP-toxicity regulatory study • Preparatory work can start on this during our initial 12-months funding • Gathering quotes from leading CROs (CRL/Charles river) • On strength of in vivo PoC data and • Developing a SoW new IP from
Slide 17: Summary
Summary • Strong market and investor focus on the delivery of RNA therapy, following the success of Covid vaccines • Invest at early stage/ attractive valuation, in an siRNA product which meets an unmet clinical need in the growing market of ophthalmology • Opportunity to target other anti-fibrotic
Slide 18: Thank you
Thank you info@n4pharma.com www.n4pharma.com 18
Thalia Therapeutics — Investor Presentation (October 2023) on 6ix